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Abstract 
 
Background: Mucosal-associated invariant T (MAIT) cells comprise a subpopulation of 
T cells that can be activated by bacterial products and cytokines to produce TNFα, IL-17, 
and granzymes. Little is known about the role of MAIT cells in fibrosis progression in 
fatty liver disease. Aim: To assess frequency and phenotype of MAIT cells and their 
correlation with liver fibrosis severities in NAFLD patients.  
Methods: twenty five NAFLD patients and five healthy donors were recruited. Age, Body 
mass index, alanine aminotransferase, serum-fasting-insulin levels, hemoglobin A1c, 
homeostatic model assessment for insulin resistance score, triglycride, high density 
lipoprotein, low density lipoprotein and c-reactive protein were correlated with fibrosis-
scoring in adult NAFLD cases lacking metabolic-syndrome or other liver etiologies. In 
vitro, peripheral blood samples were obtained from both the patients and healthy. Then 
using direct human T cell isolation kit, CD3
+ 
T cells were extracted. Using Flow 
cytometry, MAIT cells were identified by the expression of CD161 and TCR Vα7.2. For 
immune phenotyping, markers like TNFα, CD69, CD38 and IL17 were used. Then the 
serum cytokine levels were detected using quantibody human cytokine array 1. Using 
Flow cytometry, the expression of insulin receptor were determined in three patients with 
cirrhosis.  
Results: a total of 25-cases fulfill inclusion/exclusion criteria, all were males, mean age at 
biopsy 39.3±9.8y, BMI 29.19±9. Seven had cirrhosis as their fibrosis stage were 4. Serum 
HOMA-IR found the most significant predictor for histological severity. Healthy donors 
had 12.68%±1.11 MAIT cells which was significantly decreased in peripheral blood of 
patients with NAFLD 10.62%±1.37, 3.9%±0.71, 1.66%±0.08 and 1.2%±0.21 with fibrosis 
grades of F1, F2, F3 and F4, respectively. Moreover, MAIT cells from patients showed 
higher expression of activation markers such as CD69 and CD38 as compared to heathy 
donors. MAIT cells had also elevated IL-17 expression, a pro-fibrogenic cytokine as well 
as TNFα, a pro-inflammatory cytokine. These results were linearly correlated with fibrosis 
severities. Singnificant elevation was founded in the inflammatory cytokines including IL-
12 that known to activate MAIT cells. Downregulation in insulin receptor was observed in 
patients with cirhosis as compered with healthy donors. 
IV 
 
Conclusions: Decreased expressions of peripheral blood MAIT cells in NAFLD patients 
were inversely correlated with the fibrosis stage. Our data suggest MAIT cells might 
contribute to the development of fibrosis in NAFLD and represent a novel diagnostic 
target. 
 
 
 
 
V 
 
 
 
Table of Contents 
Declaration………………………………………………………………………….. I 
Acknowledgements………………………………………………………………… II 
Abstract……………………………………………………………………………... III 
Table of contents…………………………………………………………………… V 
List of Table ………………………………………………………………………... VIII 
List of Figures……………………………………………………………………… IX 
List of Appendices…………………………………………………………………. XI 
List of Abbreviations……………………………………………………………….. XII 
Chapter one: Introduction………………………………………………………... 1 
1.1Background……………………………………………………………………… 1 
1.2Nonalcoholic fatty liver disease…………………………………………………. 3 
1.2.1. NAFLD definition…………………………………………………………… 3 
1.2.2. NAFLD etiology……………………………………………………………... 3 
1.2.3. NAFLD pathophysiology……………………………………………………. 4 
1.2.4. NAFLD diagnosis……………………………………………………………. 6 
1.2.5. NAFLD scoring system……………………………………………………… 6 
1.2.6. NAFLD treatment…………………………………………………………… 7 
1.3Mucosal-associated invariant T (MAIT) cells…………………………………... 7 
1.3.1. MAIT cell discovery…………………………………………………………. 7 
1.3.2. MAIT cell an innate-like T lymphocyte……………………………............... 8 
1.3.3. MAIT cell phenotype………………………………………………………… 8 
1.3.4. MAIT cells tissue distribution……………………………………………….. 10 
1.3.5. MAIT cell activation…………………………………………………………. 11 
1.3.6. MAIT cells in diseases……………………………………………………….. 13 
VI 
 
 
1.3.7. MAIT cells in diabetic and obese patients…………………………………… 14 
1.3.8. MAIT cells in liver…………………………………………………………... 15 
1.4 Problem Statement……………………………………………………………… 16 
1.5 Study justification……………………………..................................................... 17 
1.6 Study Aims……………………………………………………………………... 17 
1.7 Hypothesis……………………………………………………………………… 17 
Chapter Two: Materials and Methods…………………………………………... 18 
2.1 Materials………………………………………………………………………... 18 
2.2 Methods………………………………………………………………………… 02 
2.2.1 Study Population………………….................................................................... 02 
2.2.2 Ethical considerations………………………………………………………… 01 
2.2.3 Clinical characterization……………………………………………………… 01 
2.2.3.1. Homeostasis Model Assessment –insulin resistance HOMA-IR………….. 21 
2.2.3.2.NAFLD activity score (NAS)………………………………………………. 21 
2.2.3.3.fibrosis score (Metavir)…………………………………………………….. 22 
2.2.4 Sample Collection and Preparation…………………....................................... 20 
2.2.5 Isolation of T cells using direct human T cell isolation kit………………….. 20 
2.2.6 Flow cytometric analysis…………………………………………………….. 20 
2.2.7 Insulin receptor detection by flow cytometeric analysis……………………... 23 
2.2.8 Cytokine measurement………………………………...................................... 24 
2.2.9 Statistical analysis……………………………………………………………. 24 
Chapter Three: Result……………………………………………………………. 25 
3.1 HOMA-IR scores are associated with increased liver fibrosis…………………. 05 
3.2 Depletion in the frequency of MAIT cells in F4 NAFLD patient………............ 06 
3.3 Activation of MAIT cells is associated with increased liver fibrosis…………... 08 
3.4 Increased the frequency of IL-17
+ 
MAIT cells is correlated with increased   
VII 
 
 
Arabic abstract ……………………………………………………………………….89 
 
 
 
 
 
 
 
 
 
 
 
 
 Liver fibrosis………………………………………………................................. 30 
3.5 Increased TNF-α expression in F4 NAFLD patients…………………………… 32 
3.6 Alterations in the cytokine levels in the serum of NAFLD patients.................... 33 
3.7 Decreased expression of insulin receptor in F4 NAFLD patients……………… 35 
Chapter Four: Discussion………………………………………………………… 36 
4.1 Discussion………………………………………………………………………. 36 
4.2 Conclusion……………………………………………………………………. 39 
4.3 Weaknesses or limitations in the current study plan………………………..... 39 
4.4 Recommendations………………………………………………………..…… 39 
4.5 Funding…………………………………………………………………………. 40 
References…………………………………………………………………………. 41 
Supplementary materials………………………………….……………………… 45 
VIII 
 
 
Lists of Table 
 
Table (3.1) Characteristics of NAFLD patients, according to Fibrosis score……...… 26 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IX 
 
 
Lists of Figures 
Figure (2.1) Flow chart for methodology that was used……………………………..  20 
Figure (3.1.A) Representative dot plot of flow cytometry analysis of the CD3
+
 cells…. 27 
Figure (3.1.B) Gate drawn on our potential population, identified asVα7.2+CD161+….. 27 
Figure(3.1.C) Percentages of MAIT cells among T cells in patients with NAFLD 
stages……………………………………………………………………………………  
 
27 
Figure (3.2.A) Flow cytometry dot plot represents the percentages of CD69 expressing 
cells……………………………………………………………………………………… 
 
28 
Figure(3.2.B) Percentages of CD69+ cells among MAIT cells in patients with NAFLD 
stages…………………………………………………………………………………….. 
 
29 
Figure(3.2.C) Percentages of CD38+ cells among MAIT cells in patients with NAFLD 
stages…………………………………………………………………………………...... 
 
29 
Figure (3.2.D) The correlation between MAIT cells frequency and CD69 expression…. 30 
Figure (3.3.A) A flow cytometry dot plot represents the percentages of IL-17+ MAIT 
cells………………………………………………………………………………………  
 
31 
Figure (3.3.B) Percentages of IL-17+ cells among MAIT cells in patients with NAFLD 
stages……………………………………………………………………………………. 
Figure (3.3.C) The correlation between MAIT cells frequency and IL-17+ MAIT cells…………… 
 
31 
32 
Figure (3.4.A) A flow cytometry dot plot represents the percentages of TNF-α+ MAIT 
cells………………………………………………………………………………………. 
 
32 
Figure(3.4.B) Percentages of TNF-α+ cell among MAIT cells in patients with NAFLD 
stages…………………………………………………………………………………… 
 
33 
Figure (3.5) Means of the cytokine level detected in the sera of 5 patients from each 
fibrosis stage F1, F2 and F4 and 5 healthy donors……………………………………... 
 
34 
X 
 
 
 
 
 
Figure (3.6) Percentages of insulin receptor
+ 
cell among MAIT cells in patients  
NAFLD with F4 stage…………………………………………………………………… 
 
35 
XI 
 
 
List of Appendices 
 
Appendix 1 Approval consent 
Appendix 2 Direct human T cell isolation kit 
Appendix 3 Quantibody human cytokine array 1 kit 
 
 
 
  
XII 
 
 
List of abbreviations  
 
AST Aspartate Transaminase 
ALT Alanine Transaminase 
ABC ATP binding cassette 
APC Allophycocyanin 
BCL2 B Cell Lymphoma 2 
BMI Body Mass Index 
CRP  c-reactive protein 
CLOCK Circadian Locomotor Output Cycles Kaput 
CT Computed Tomography 
CRN Clinical Research Network 
CD Cluster of Differentiation 
CCR C-C Chemokine Receptor 
CXCR C-X-C Chemokine receptor 
CXCL C-X-C Chemokine Ligand 
DENV  Dengue virus 
FFA  Free Fatty Acid 
FITC Fluorescein Isothiocyanate 
FTO Fat mass and obesity-associated  
GM-CSF Granulocyte Macrophage- Colony Stimulating Factor 
Gr Granzyme 
HOMA-IR Homeostatic Model Assessment for Insulin Resistance 
HbA1c Hemoglobin-A1c 
HCV  Hepatitis C Virus 
HLA-DR Human Leukocyte Antigen- antigen D Related 
HSC Hepatic Stellate Cells 
HIV  Human Immunodeficiency Virus 
HMOX-1 heme oxygenase-1  
IRS Insulin Receptor Substrate 
IFN-γ Interferon γ 
IgG immunoglobulin G 
MAIT  Mucosal Associated Invariant T 
MHC Major Histocompatibility Complex 
MR1  MHC class I-Related protein 1 
MRI Magnetic Resonance Imaging 
mAbs  Monoclonal Antibodies 
MMP9 Matrix Metallopeptidase 9 
NAFLD Non Alcoholic Fatty Liver Disease 
NASH Non-Alcoholic SteatoHepatitis 
NAS NASH Activity Score 
NKG2D Natural Killer Group2 member D 
NOD Non Obese Diabetic 
NF-κβ Nuclear Factor Kappa Beta 
5-OP-RU 5-(2- oxoethylideneamino) -6-D-ribitylaminouracil 
5-OE-RU  5-(2-oxopropylideneamino) -6-D-ribitylaminouracil 
XIII 
 
 
PD-1 Programmed Death-1 
PBS Phosphate Buffer Saline 
PE Phycoerythrin 
PNPLA3 Patatin-Like Phospholipase Domain Containing 3 
PerCP Peridinin Chlorophyll Protein Complex 
PB Pacific Blue 
PBMCs Peripheral Blood Mononuclear Cells 
PXR Pregnane X Receptor  
pg/ml Picograms per Milliliter 
PLZF Promyelocytic Leukemia Zinc Finger 
PMA Phorbol 12-Myristate 13-Acetate 
RORγt Retinoic Acid-Related Orphan Receptor γt 
ROS Reactive Oxygen Species 
Sags  Superantigens 
STAT3 Signal Transducer And Activator Of Transcription 3 
T-bet T- Box Expressed in T cells 
T2D type2 diabetes 
T1D type 1diabetes 
TCR  T Cell Receptor 
TG Triglycerides 
TE  Transient Elastography 
TNF-α Tumor Necrosis Factor α 
US Ultrasonography 
Vα7.2/ Jα33 Variable region α7.2, Joining region α33 
Vβ13 Variable region β13 
 
 
 
1 
 
 
 
 
 
 
 
 
 
Chapter One 
 
Introduction 
 
1.1 Background  
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of disease that ranges from 
simple steatosis to the more progressive form terms as non-alcoholic steatohepatitis. 
NASH is the major cause of chronic liver fibrosis characterized by excessive extracellular 
matrix accumulation in liver cells which is accompanied by inflammation and injury and 
can lead to cirrhosis, liver failure and eventually carcinoma (Zhang et al., 2018). 
 
 NAFLD is the most common chronic liver disease with estimated prevalence 6-35% 
worldwide (Cobbina & Akhlaghi, 2017). The prevalence of NASH is 3%-5% in the 
general population which is considered as the leading cause of morbidity and mortality 
from liver disease (Ashtari et al., 2015). NAFLD is associated with metabolic syndromes 
such as obesity, diabetes, insulin resistance and dyslipidemia. It is plausible that the 
prevalence of NAFLD is increasing because of the obesity epidemic (Oh et al., 2016). 
 
A liver biopsy is the gold standard method for diagnosis of NAFLD. However, the 
sampling error is a major concern; especially that only 1/50000 of the whole liver tissue is 
sampled during a liver biopsy. Therefore, there is a need for the noninvasive method used 
for the detection of patients with NAFLD (Amer et al., 2018). 
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The liver is the immunologic organ that is in continuous exposure to microbial and food 
antigens from the gut. The presence of MAIT cells in mucosal barrier, the highly 
enrichment of MAIT cells in the liver and their rapid antimicrobial function render MAIT 
cells a plausible population that might contribute to both the maintenance of liver and the 
inflammation of liver in disease (Bolte & Rehermann, 2018; Kurioka et al., 2016). 
 
MAIT cells represent the most abundant subset of non-conventional T cells. MAIT cells 
express semi-invariant T cell receptor (TCR Vα702-Jα33\12\20). Furthermore, MAIT cells 
are restricted to nonpolymorphic major histocompatibility complex (MHC) class Ib 
molecule, MHC class I-related protein 1 (MR1), that presented non-protein antigens, that 
include derivatives of riboflavin and folic acid synthesis pathways in bacteria, 
mycobacteria, and yeast. MAIT cells can be activated by TCR dependent manner as 
conventional T cell. Moreover, it can be activated like other innate T cells by cytokines 
dependent manner such as interleukin12 (IL-12) and IL-18. Upon activation, these cells 
express pro-inflammatory cytokines such as interferon γ (IFN-γ) and tumor necrosis factor 
α (TNF-α) and they release cytotoxic and pro-inflammatory granzymes, such as granzyme 
B and perforin (Kurioka et al., 2016; Xiao & Cai, 2017) 
  
MAIT cells have a wide tissue distribution, they comprise 5% of T cells in peripheral 
blood, 60% in the jejunum, and they present also in colon, lung, cervix, kidneys, ovaries, 
and others. MAIT cells represent the major T cell population in the liver in about 20%-
50% of T cells, this high frequency suggests that they have a role in the immunity of liver 
and in the pathophysiology of liver inflammation in diseases (Gapin, 2014). 
 
However, the circulating MAIT cells decreased in the obese patients and type 2 diabetes 
(T2D) patients, their activation is increased as defined by CD25 and CD69 expression and 
their production of IL-17, IL-2 and GrB are markedly increased (Magalhaes et al., 2015b). 
MAIT cells have the ability to express IL-17 under the control of cytokines IL-1β, IL-23 
and IL-7 that found to be released by the hepatic stromal cell, confirm the link between 
liver and MAIT cells (Ussher et al., 2014). 
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1.2 Nonalcoholic fatty liver disease 
1.2.1. NAFLD definition  
Non-alcoholic fatty liver disease (NAFLD) is a spectrum disease defined by excessive fat 
accumulation in the form of triglycerides (steatosis) in more than 5% of hepatocytes that is 
not a result of alcohol consumption or other causes such as viral hepatitis or medications 
(Paschos & Paletas, 2009; Zhang et al., 2018). Most NAFLD patients are asymptomatic 
but 30% of them progress to the aggressive form non alcoholic steatohepatitis (NASH) in 
which excessive steatohepatitis accompanied with liver cell injury and inflammation that 
characterized by ballooning, apoptosis/necrosis, Mallory’s hyaline and giant mitochondria 
and eventually fibrosis (Khedmat & Taheri, 2011; Zhang et al., 2018) 
 
Non-alcoholic steatohepatitis (NASH) was firstly described in 1980 by Ludwig et al. 
(Pascale et al., 2010). NASH firstly was considered as a benign condition until that more 
studies revealed that NASH can be progressive and may lead to cirrhosis and liver failure 
(Zhang et al., 2018). NASH hepatic injury is similar to alcoholic fatty liver, however, 
NASH seems to progress more slowly and is histologically less severe than steatohepatitis 
caused by alcohol (Vernon et al., 2011).  
 
NAFLD is the most common chronic liver disease worldwide with estimated NAFLD 
prevalence in Western countries 20-30%, whereas 12%-24% in Asian countries (Ashtari et 
al., 2015). 20% of NASH may progress to cirrhosis. NASH increases the risk of 
hepatocellular carcinoma and liver failure by 10-folds and doubling the risk of 
cardiovascular diseases (Zhang et al., 2018). NASH increases the liver-related mortality by 
3-fold than the general population (Pappachan et al., 2017). 
 
1.2.2. NAFLD etiology 
There is no precise known etiology of NAFLD. However, the major risk factors of NAFLD 
development are well established, including age, gender, insulin resistance, type 2 diabetes 
mellitus, increased ferritin levels and genetic factors (Byrne & Targher, 2015). NAFLD 
has been reported in all age groups. However, a higher prevalence of NAFLD and fibrosis 
are reported with increasing age that might attribute to the risk factors present in elderly 
(Mishra & Younossi, 2012). Although there is a discrepancy between studies in the 
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predominant gender, NAFLD is found to occur more frequently in men (Khedmat & 
Taheri, 2011).  
  
Metabolic syndrome is defined by the presence of three or more of the following factors: 
elevated waist circumference, elevated triglycerides or on drug treatment for elevated 
triglycerides, reduced HDL level, hypertension or on antihypertensive drug treatment, 
Type 2 diabetes, Family history of diabetes, overweight, cardiovascular complications, 
impaired fasting glucose or on antidiabetic drug treatment and insulin resistance (Paschos 
& Paletas, 2009). There is a strong association between NAFLD and metabolic syndrome. 
Therefore, the prevalence of NAFLD and NASH are increasing as obesity became an 
epidemic worldwide (Vernon et al., 2011). 
 
1.2.3. NAFLD pathophysiology 
The second hit hypothesis was firstly proposed in which hyperglycemia and insulin 
resistance lead to steatosis, is the first hit, and the oxidative stress and pro-inflammatory 
cytokines can lead to hepatocyte apoptosis, recruitment of inflammatory cells and may 
progress to fibrosis, is the second hit (Khedmat & Taheri, 2011; Zhang et al., 2018). 
However, the pathogenesis of NAFLD was observed to be more complex and depending 
on genetic, nutritional and environmental factors. The development of NAFLD and 
progression of NASH is based on the timing and combination of the factors (Buzzetti et 
al., 2016). 
 
Abnormal steatosis in hepatocytes is an essential process in the pathgenesis of NAFLD. 
The source of these lipids is from the systemic circulation, de novo synthesis, reduced 
degradation and reduced export from hepatocytes. Storing lipids as triglycerides is not 
directly hepatotoxic, whereas diacyl glycerols, cholesterol, phosphatidylcholines, and 
certain saturated fatty acids (FAs) are particularly toxic (Kara et al., 2018). 
 
Insulin resistance (IR) is a key factor in NAFLD development. Insulin resistance increases 
adipocyte lipolysis by decreasing its inhibitory action on hormone-sensitive lipase in 
adipose tissue, leading to increasing free fatty acid (FFA) in circulation, thus enhance liver 
uptake of FFA (Paschos & Paletas, 2009). Hyperinsulinemia enhances de novo lipogenesis 
and inhibiting β oxidation that lead to lipid accumulation in the liver (Buzzetti et al., 2016). 
5 
 
 
In addition, insulin resistance reduces plasma adiponectin levels that increase insulin 
sensitivity and reduce inflammation and increase adipocyte cytokine leptin that plays a role 
in reducing body weight and fat mass (Pappachan et al., 2017). Homeostatic model 
assessment for insulin resistance (HOMA-IR) is a sensitive and specific method for 
measuring IR. HOMA–IR measurement based on serum fasting glucose and insulin levels 
(Buzzetti et al., 2016). 
 
Steatosis activate the transcription factor nuclear factor kappa b (NF-κβ) which lead to 
increase the production of pro-inflammatory cytokines such as tumor necrosis factor α 
(TNF-α), interleukin (IL-6) and IL-1β which results in the recruitment and the activation of 
kupffer cells, thus lead to inflammation condition (Cobbina & Akhlaghi, 2017). 
 
Other potential process may interfere with the pathogensis of NAFLD is the alterations in 
the composition and functions of the gut microbiota have been found to be associated with 
NAFLD development (Pappachan et al., 2017). Gut microbiota can activate toll- like 
receptor 4 (TLR-4) which is an activator to NF- κβ and can also intervene in the 
metabolism of the secondary bile acids such as deoxycholic acid that found to be 
associated with the pathogenesis of hepatocellular carcinoma (Byrne & Targher, 2015).  
 
Mitochondrial dysfunction which may happen as a result of excess fatty acid in the liver, 
leads to the formation of lipid-derived toxic material and overproduction of reactive 
oxygen species (ROS) in which they can activate kupffer cell and hepatic stellate cell 
causing necrosis, inflammation, and fibrosis (Buzzetti et al., 2016).  
 
Studies have identified many genetic changes that may be associated with the susceptibility 
and progression of NAFLD. Among these are polymorphisms involved in the circadian 
rhythm (CLOCK transcription factor), the signal transducer and activator of transcription 3 
(STAT3), the multidrug resistance-associated protein gene (ABCC2), the nuclear pregnane 
X receptor (PXR), heme oxygenase-1 (HMOX-1), Fat mass and obesity-associated (FTO) 
and PNPLA3 gene (Pappachan et al., 2017; Sookoian & Pirola, 2017). PNPLA3 gene is 
found in adipocytes and hepatocytes. It is thought to help regulate the lipogenesis and 
lipolysis and the development of adipocytes. The PNPLA3 gene variation associated 
with NAFLD is thought to lead to increased production and decreased breakdown of fats in 
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the liver. Research is ongoing to determine how the genetic changes contribute to the 
development of NAFLD and its complications (Kara et al., 2018). 
 
1.2.4. NAFLD diagnosis 
A liver biopsy is the gold standard method for staging the disease. However, due to its 
invasiveness, procedure complications, histopathologist variation and the cost, many other 
methods were found to diagnose NAFLD (Torres & Harrison, 2008). Liver 
aminotransferase AST and ALT levels are the most commonly used methods for screening 
of NASH. The ALT levels are higher than the AST levels in most cases, however, many 
individuals with severe NASH have more elevated AST serum level than ALT (Khedmat 
& Taheri, 2011). Other non invasive method is serological markers, such as serum 
autoantibodies. Antinuclear antibodies are strongly associated with insulin resistance, 
reactive oxygen species (ROS), adiponectin and leptin as markers for insulin resistance, 
increased c-reactive protein (CRP), cytokeratin 18 marker for hepatic apoptosis. Moreover, 
imaging techniques are commonly used in NAFLD diagnosis such as ultrasonography 
(US) which has high sensitivity, but without accurate staging of steatosis and with obesity 
decreasing sensitivity of the method. Computed tomography CT is accurate and sensitive, 
however, cannot distinguish simple steatosis from steatohepatitis. Magnetic resonance 
imaging (MRI) is the most accurate method for diagnosis and quantification of hepatic 
steatosis, with specificity, sensitivity and safety of MRI making it an ideal methodology to 
assess and monitor hepatic steatosis. The limitations are the cost and the inability to 
distinguish between NASH and NAFLD. Transient elastography (TE) provides an 
estimation of liver stiffness and it is accurate in diagnosis of severe liver fibrosis but not in 
the early stages. These methods are unreliable in the differentiation between NAFLD and 
NASH (Paschos & Paletas, 2009; Torres & Harrison, 2008) .  
 
1.2.5. NAFLD scoring system 
To predict the progression of liver fibrosis, scoring systems using a combination of clinical 
and laboratory parameters were established such as BAAT system based on BMI, age, 
ALT and serum TG. Fibrotest that used markers of collagen synthesis and degradation, 
including α2-macroglobulin, Haptoglobin, total bilirubin and apolipoprotein A1 and 
NAFLD fibrosis score used age, body mass index, platelet count, albumin level and 
AST\ALT ratio (Oh et al., 2016; Torres & Harrison, 2008). 
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A liver biopsy is a reliable method for diagnosis, staging and predicts the prognosis of 
NASH. Systems to standardize the interpretation of the histological diagnosis were 
established (Oh et al., 2016). Burnt system, classified NAFLD into three types: mild, 
moderate and sever based on steatosis, hepatocellular ballooning degeneration, lobular and 
portal vein inflammation. In addition, this system classified liver fibrosis into four stages 
(Oh et al., 2016). Activity Score (NAS), proposed by the NASH Clinical Research 
Network (CRN) is calculated by the sum of scores of steatosis (0-3), lobular inflammation 
(0-3) and hepatocyte ballooning (0-2) with final score ranging from 0 to 8. If NAS score 
was less than 3 then it is correlated with non-NASH, whereas score of 3-5 is considered 
suspicious NASH and more than 5 is definitive NASH (Juluri et al., 2011).  
  
1.2.6. NAFLD treatment: 
 There is no fully effective treatment for NAFLD. However, to improve the steatosis and 
prevent the progression, treatment of the underlying risk factors are intervened, including 
lifestyle intervention such as weight loss, increase physical activity, diet (Pappachan, 
Babu, Krishnan, & Ravindran, 2017). A 7%-10% weight loss is required to improve 
hepatic inflammation but the minority of patients are able to do (Zhang et al., 2018). 
Antioxidants drug, insulin-sensitizing drugs such as Metformin, thiazolidinediones, and 
lipid-lowering drugs are used to improve the metabolic conditions (Torres & Harrison, 
2008). 
 
1.3 Mucosal-associated invariant T (MAIT) cells 
1.3.1. MAIT cell discovery  
Mucosal-associated invariant T (MAIT) cells are a subset of innate-like T lymphocytes, 
first described in 1993 by Porcelli et al. as a new T cell population expressed invariant 
TCR-α chain Vα7.2Jα33 (Gapin, 2014; Napier et al., 2015; Xiao & Cai, 2017). In 1999, 
Treiner et al. observed that these cells are conserved within mammalian species. Later, in 
2003, Treiner et al. gave the name MAIT cells for them as they found that they are 
enriched at the mucosal tissue, including the gut lamina propria. They also described the 
monomorphic class I-related MHC molecule, MR1, as the restricted antigen presenting 
molecule for MAIT cells (Xiao & Cai, 2017). Two studies in 2010, Le Bourhis et al. and 
Gold et al. showed the antimicrobial activity of MAIT cells against bacteria and fungi 
(Gapin, 2014; Howson et al., 2015; Kurioka et al., 2016; Napier et al., 2015; Reantragoon 
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et al., 2016). In 2012, the discovery of MR1 ligands by Kjer-Nielsen et al. which were 
vitamin B2 pathway metabolites, led to conclusion that MAIT cells are activated by 
microbes possess the riboflavin pathway (Chiba et al., 2017; Hinks, 2016; Howson et al., 
2015). 
 
1.3.2. MAIT cell an innate-like T lymphocyte 
MAIT cells are non-conventional T cells act as a bridge between the adaptive and innate 
immunity. Like conventional T cells, they are TCR and MHC dependent cells, however, 
they express a semi‐invariant TCR‐α chain that has a limited diversity, and they are 
restricted to non-polymorphic MHC class I-related molecule, MRI, that presents vitamin 
B2 derivatives unlike to conventional T cells that are activated by peptide antigen presented 
by MHC-I or MHC-II (Brozova et al., 2016; Howson et al., 2015; Xiao & Cai, 2017). 
MAIT cells like conventional T cells undergo TCR rearrangement and positive selection in 
thymus but unlike conventional T cells that require an antigenic activation in the periphery 
to gain the effector function. MAIT cells acquire it in the thymus that makes MAIT cells 
similar to innate immune cells in the speed of response (Napier et al., 2015). Despite that 
MAIT cells are developed in the thymus, they have a distinct development pathway from 
the conventional T cells (Chandra & Kronenberg, 2015). Phenotypically, MAIT cells 
egress the thymus naïve as the conventional T cells then in the periphery they gain the 
memory phenotype (Howson et al., 2015; Napier et al., 2015). MAIT cells also produce 
pro-inflammatory cytokine and cytotoxic molecules upon activation in similar to 
conventional CD8
+
 effector T cells (Chandra & Kronenberg, 2015; Napier et al., 2015). 
 
1.3.3. MAIT cell phenotype 
MAIT cells are subset of αβ T cells characterized by a semi-invariant TCR-α chain with 
highly abundant in human Vα7.2-Jα33 although Vα7.2-Jα12 or Vα7.2-Jα20 are also found 
by a minority of MAIT cells, and associated with β chains predominance with Vβ13 and 
Vβ2 (Brozova et al., 2016; Kurioka et al., 2016; Xiao & Cai, 2017). This invariant TCR 
and MR1 are conserved in mammalian species (Xiao & Cai, 2017).  
 
MAIT cells have a naïve phenotype after migration from thymus, in the periphery they 
exhibit memory phenotype CD45RO+, CCR7-, CD62Llo, CD95
hi
, CD122
int
, CD127
hi
, this 
memory phenotype is termed as effector memory-like due to the absent of CD62L and 
9 
 
 
CCR7, and the quick response to stimulation that resemble to conventional effector 
memory T cells (Berkson & Prlic, 2017; Howson et al., 2015; Kurioka et al., 2016; Napier 
et al., 2015; Reantragoon et al., 2016; Ussher et al., 2014). 
 
MAIT cells also express the transcription factor promyelocytic leukemia zinc finger 
(PLZF) which is responsible for the innate-like effector function in nonconventional T 
cells (Berkson & Prlic, 2017; Napier et al., 2015). Other transcription factors express on 
MAIT cells are Helios, Eomes, T-bet that associated with IFN-γ production and retinoic 
acid-related orphan receptor (ROR) γt which associated with the ability to produce 
interleukin-17 (IL-17) (Kurioka et al., 2016; Ussher et al., 2014). NKG2D is transcription 
factor also express by MAIT cells that activate NK receptor and enhance the cytotoxicity 
in NK cell (Brozova et al., 2016).  
 
The high and early expression of the C-type lectin-like receptor is used in the definition of 
MAIT cells with co-expression of TCR α chain Vα.7.2+ CD161++ in many studies 
(Kurioka et al., 2016). MAIT cells can also be defined by the unique high expression of 
IL-18R (Ussher et al., 2014). MAIT cells also express cytokine receptors, including IL-7α, 
IL-12R, IL-18R, IL-2Rβ and IL-23R, activation markers such as, CD25, CD69 and CD38, 
and tissue homing receptors such as, CCR2, CCR5, CCR6, CXCR6, CCR9, CD103 and 
α4β7 integrin which indicate their ability to migrate to tissue as well as to the site of 
infection(Howson et al., 2015; Kurioka et al., 2016; Reantragoon et al., 2016; Xiao & Cai, 
2017). The proliferation marker Ki67 is found to be expressed by MAIT cells which 
indicate the proliferation ability of MAIT cells in the presence of IL-1 and IL-8 
(Reantragoon et al., 2016). 
 
MAIT cells have three subsets: the predominance CD8+ with 95%of MAIT cell express 
the homodimer form CD8αα than CD8αβ unlike to the CD8+conventional T cell that 
expresses CD8 αβ only (Brozova et al., 2016; Kurioka et al., 2016). Other subsets are 
double negative DN and only 2-11% of MAIT cells in blood express CD4 (Kurioka et al., 
2016; Xiao & Cai, 2017). These subtypes are shown to have discrepancies in their 
frequency and function. As DN MAIT cells are more resistant to aging than CD8+ MAIT 
cells, but CD8+ MAIT cells produce more INF-γ and IL-17 than DN MAIT cells. 
Moreover, the CD8+ MAIT cells, mainly produce Th1 cytokine such as INF-γ, whereas 
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CD4+ subset produces both Th1 and Th2 cytokine, like INF-γ and IL-4 (Brozova et al., 
2016; Lee et al., 2014). MAIT cells are a heterogeneous group in their phenotype and 
activation response that might render to the diversity of β chain, despite the early 
consideration that MAIT cells are homogeneous group due to the conserved MR1 and the 
limited ligands are known to date (Dias et al., 2017). It is also found that the circulating 
MAIT cell frequencies increased with age to reach the adult levels, then decline with age 
irrespective of the gender (Lee et al., 2014). 
 
1.3.4. MAIT cells tissue distribution 
The expression of the chemokine receptor CCR9, CXCR6 and gut homing integrin α4β7 
and CCR9
lo
, conferring MAIT cells' ability to home in tissue especially in the liver, lung, 
and intestine. Due to the lack of CCR7 and CD62L expression, MAIT cells are not 
qualified to home in lymph nodes (Kurioka et al., 2016).  
 
MAIT cells are enriched in the intestine with different frequency in different anatomical 
location, a higher frequency found in the jejunum of about 60%of T cells, colon (10% of T 
cells), and lower frequency in ileum and rectum. MAIT cells also enriched in the liver with 
about 20-50% of T cells, in the blood of 1-10% of T cells, in lung, kidney, prostate, ovaries 
(Howson et al., 2015; Kurioka et al., 2016). 
 
It was found that MAIT cells differ in their phenotyping according to the tissue. For 
instance, a study about the analysis of the α-chains found out that in tissue the 
predominance was Vα7.2-Jα12, whereas Vα7.2-Jα33 was in the blood (Howson et al., 
2015). Another study revealed that fetal mucosal tissue and the female genital tract MAIT 
cells produce more IL-17 and IL-22 than MAIT cells in blood when stimulated with either 
bacteria or phorbol 12-myristate 13-acetate (PMA) /ionomycin (Berkson & Prlic, 2017; 
Pappachan et al., 2017). Moreover, almost all liver MAIT cells found to express high 
levels of the activation marker CD69, CD38, and HLA-DR and be more active than those 
in blood, this reflects the continuous antigen exposure (Howson et al., 2015; Kurioka et al., 
2016). 
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1.3.5. MAIT cell activation 
MAIT cells are functionally defined as innate-like T cells that can rapidly produce pro-
inflammatory cytokine mainly Th1 type cytokines (INF-γ, TNF-α) and Th-17 type 
cytokines (IL-17, IL-22), and cytolytic products such as granzymes mainly GrA, K, B and 
perforin which give them the ability to kill the infected cells (Howson et al., 2015; Kurioka 
et al., 2016; Xiao & Cai, 2017). They also have the ability to help B cells (Xiao & Cai, 
2017). Since MAIT cells produce IL-17 and IL-22, it is suggested that they have a role in 
epithelial integrity and tissue homeostasis (Berkson & Prlic, 2017).  
 
MAIT cells can be activated by the MR1 dependent manner in which antigen-presenting 
cells present metabolites derived from the riboflavin biosynthetic pathway of bacteria and 
yeast interact with MHC class I-related protein (MR1). Therefore, MAIT cells are 
activated by bacteria and yeasts possessing the riboflavin synthetic pathway, including 
Mycobacterium. abscessus, E.coli, Salmonella. enterica, Klebsiella. pneumonia, 
Staphylococcus. aureus, Staphylococcus. epidermidis, Pseudomonas. aeruginosa, 
Lactobacillus. acidophilus, Candida. glabrata, C. albicans, and Saccharomyces. 
Cerevisiae (Kurioka et al., 2016). MR1 widely expressed across a various cells including 
professional antigen presenting cells, epithelial cells and monocytes (McWilliam & 
Villadangos, 2017; Riva et al., 2018). The majority of MR1 in the absence of ligand 
resides in the endoplasmic reticulum ER, and in the presence of the ligand, MR1 has a 
conformational change, including binding to β2-microglobulin and then the complex MR1- 
β2-microglobulin-ligand egress to the cell surface to present the legend to MAIT cells 
(McWilliam & Villadangos, 2017). MR1 present the pyrimidine intermediates from the 
riboflavin pathway after the condensation with glyoxal and methylglyoxal molecules 
derived from metabolic pathways including glycolysis (Keller et al., 2017). The most 
potent MAIT cells activating ligands are pyrimidine compounds 5-(2-
oxopropylideneamino) -6-D-ribitylaminouracil (5-OP-RU) and 5-(2- oxoethylideneamino) 
-6-D-ribitylaminouracil (5-OE-RU) (McWilliam & Villadangos, 2017). MR1 can present 
molecules derived from the folic acid pathway, in addition to riboflavin pathway 
intermediates, however, these molecules do not activate MAIT cells. Drugs and drug-like 
molecules can also be presented by MR1 and can affect the function of MAIT cells (Keller 
et al., 2017). A study by Dias et al. suggest that MAIT cells can adjust their response to fit 
the different antigenic microbes. In this study they found a different response of MAIT 
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cells toward E.coli and C.albicans, in which the response against E.coli showing most 
rapid production of INF-γ and TNF-α than did in C.albicans (Dias et al., 2017). 
 
MAIT cells also shown to be activated in bacterial and viral infections which lack the 
riboflavin pathway, and in the non-infectious diseases that confirm the activation of MAIT 
cells through MR1 independent manner. MAIT cells can be stimulated by IL-18 in synergy 
with other inflammatory cytokines such as IL-12, IL-15, IL-7 and IL-23 (Kurioka et al., 
2016; Wong et al., 2017; Xiao & Cai, 2017). Upon activation of MAIT cells in viral 
infection, they are found to produce copious amounts of INF-γ, an antiviral cytokine, TNF-
α which have an antiviral activity such as reduce spreading of hepatitis C virus (HCV) and 
granzyme B that license cell for the cytotoxic function (Ussher et al., 2018). For the 
acquisition of the effector function of MAIT cells in a MR1 dependent manner, the 
synergy between the inflammatory cytokine signals and TCR signals is needed for efficient 
effector response. This synergy is critical since MAIT cells present in mucosal tissue that 
have commensal bacteria may produce the riboflavin metabolites. However, activation 
through inflammatory cytokine is sufficient to induce the effector function of MAIT cells 
(Berkson & Prlic, 2017; Slichter et al., 2016).  
 
A new study by Shaler et al. revealed that the activation of MAIT cells can be triggered by 
superantigens (SAgs) produced by Staphylococcus. aureus and Streptococcus. pyogenes in 
TCR Vβ dependent manner and more predominantly through cytokine manner mainly 
through IL-18 and IL-12 by producing INF-γ, TNF-α, and IL-2 but not IL-17. They also 
found that MAIT cell responsiveness to SAgs is more rapid and higher than conventional T 
cells and other non-conventional T cells including invariant natural killer T (iNKT) cells 
and γδ T cells. However, they found that the hyperinflammatory condition of MAIT cells 
toward SAgs renders them to be anergy which means they become unresponsive to 
bacterial Ag-MR1complex. These findings demonstrate the role of MAIT cells in 
antimicrobial immunity and the potency in utilizing MAIT cells in therapy of SAgs related 
diseases (Sandberg et al., 2017; Shaler et al., 2017). 
  
A newly revealed function of MAIT cells is the ability to help B cells by inducing B cell 
plasmablast and antibody production. A study by Micheal et al. found that MAIT cells 
upon activation release cytokines promote this function including, IL-2 which induce B-
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cell differentiation and proliferation, IL-6 that enhance production of IgG, IL-10 promote 
B-cell survival, proliferation, and antibody production, IL-21 promotes B-cell proliferation 
and IFN-γ augment antibody production and entry into the S phase in human B cells 
(Bennett et al., 2017). 
 
1.3.6. MAIT cells in diseases 
Many studies suggestes the important roles of MAIT cells in diseases, including infectious 
and noninfectious diseases. In 2010, Le Bourhis et al. and Gold et al. studies gave the first 
evidence in the antimicrobial role of MAIT cells. These studies found that in 
M.tuberculosis infection, the circulating MAIT cells were lower than the healthy subjects. 
Le Bourhis et al. study showed that MAIT cells frequency in ascites of a tuberculosis 
patient is higher than those in ascites from patients with malignancy. These findings 
suggest that MAIT cells might migrate to the site of infection (Le Bourhis et al., 2010; 
Reantragoon et al., 2016).  
 
In addition, Grimaldi et al. found that the early depletion in the frequency of peripheral 
MAIT cells in intensive care unit patients with sepsis was associated with increased 
susceptibility to secondary infection (Grimaldi et al., 2014). In Booth et al. in vitro study, 
MAIT cells were found to be less frequent in the blood of H.pylori patients than in healthy 
individuals, and MAIT cells of patients were able to release Th1 and Th2 cytokines and to 
kill infected macrophages (Reantragoon et al., 2016). Another study on patients with scrub 
typhus infection caused by Orientia.tsutsugamushi revealed a decrease in the frequency of 
MAIT cells in the blood of patients compared to healthy which correlate with the disease 
severity (Berkson & Prlic, 2017). 
 
Although MAIT cells are activated through recognition of MR1 presenting vitamin B2 
metabolites which are lacking in viruses, MAIT cells have the antiviral activity through a 
combination of IL-18 and other pro-inflammatory cytokines. An in vivo and in vitro study 
by Wilgenburg et al. revealed the ability of MAIT cell to be activated by dengue virus 
(DENV), hepatitis C virus (HCV) and influenza virus in MR1-independent manner (van 
Wilgenburg et al., 2016). Many studies showed the depletion in peripheral MAIT cell 
frequency in the blood of human immunodeficiency virus (HIV) patients. Moreover, 
circulating MAIT cells in HIV patients have a reversible dysfunction that restored after 
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anti-retroviral therapy (Reantragoon et al., 2016). Bolte et al. found that the frequency of 
MAIT cells was lower in the blood and liver of HCV patients when compared with 
controls. In addition, they found that the frequency of liver MAIT cells in those patients 
was inversely correlated with liver inflammation and fibrosis (Bolte et al., 2017). 
 
MAIT cells also play a potent role in the non-infectious diseases that proved in many 
studies. The frequency of peripheral MAIT cells in ankylosing spondylitis found to be 
lower than the healthy controls. However, synovial fluid of ankylosing spondylitis patients 
have a higher frequency of MAIT cells than in healthy controls, which reflect their 
recruitment to the inflamed joints. In addition, they also found that MAIT cells in synovial 
fluid highly express IL-17 phenotype in response to IL-7 activation (Gracey et al., 2016). 
Chiba et al. suggest that MAIT cells frequency is reduced in peripheral blood of patients 
with systemic lupus erythematosus, which may occur due to activation-induced cell death. 
Moreover, they observed that MAIT cell activation reflected the disease severity (Chiba et 
al., 2017). The depletion in the circulating MAIT cell frequency that was associated with 
the enrichment of MAIT cells in the inflamed tissue was observed in many conditions, 
including inflammatory bowel disease, multiple sclerosis, alcoholic liver disease and 
nonalcoholic steatohepatitis (Gapin, 2014). It is plausible that MAIT cells may have a role 
in cancer as they can produce INF-γ which enhance tumor-specific T cell responses and 
IL-17 that promote the expansion and accumulation of immunosuppressive neutrophils and 
myeloid-derived suppressor cells (Kurioka et al., 2016). In addition, MAIT cells found to 
express the ATP binding cassette (ABC) B1 drug resistance transporter which allows 
MAIT cells to efflux drugs and to persist during chemotherapy of acute myeloid leukemia 
or breast cancer (Ussher et al., 2014). 
  
1.3.7. MAIT cells in diabetic and obese patients 
Due to MAIT cell's location in mucosal tissue that makes them in close to the microbiota, 
and the fact that MAIT cells depend on microbiota in their development, it was expected 
that MAIT cells may have alterations in dysbiotic condition (Constantinides, 2018). MAIT 
cell share the ability to maintain the gut integrity and homeostasis through the production 
of IL-17 and IL-22. Alteration in microbiota is observed in patients with type 1diabetes 
(T1D), type2 diabetes (T2D) and obesity that could lead to indirectly induce MAIT cell 
activation. In addition, the plasma levels of methylglyoxal, a molecule that condenses with 
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an intermediate of riboflavin pathway to form pyrimidines which are the most potent 
MAIT cells activating ligands, are found to be elevated in T1D and T2D patients 
(Magalhaes et al., 2015a).  
 
Rouxel et al. study revealed a decrease in MAIT cell frequency in the blood of children 
with recent onset of T1D when compared to healthy children. This depletion might be due 
to the migration of MAIT cells to the site of infection, in this case, is the pancreas. They 
also showed the expression of activation and exhaustion markers including, CD25, 
programmed death-1 (PD-1) and BCL2. Moreover, they also found an increase in the 
frequency of MAIT cells in the pancreas of nonobese diabetic (NOD) mice, as well in their 
production of INF-γ and granzyme B which was found to directly contribute to pancreatic 
β cell killing (Rouxel et al., 2017). 
 
In T2D and obesity, circulating MAIT cells were found to be reduced in frequency, but had 
a higher IL-17 production. In addition MAIT cells in adipose tissue of obese patients 
showed a higher frequency and activation phenotype represented by the upregulation of 
CD25 and CD69 expression, as compared to lean controls. Similary, IL-17 production in 
adipose tissue of obese patients was increased in correlation with insulin resistance that 
might participate to the obesity-related inflammation and insulin resistance (Carolan et al., 
2015; Magalhaes et al., 2015b). After Bariatric surgery, the frequency and function of 
MAIT cells in peripheral blood of obese patients was found to be restored (Magalhaes et 
al., 2015b). 
  
1.3.8. MAIT cells in liver 
The liver is the immunologic organ that is in continuous exposure to microbial and food 
antigens from the gut. The presence of MAIT cells in mucosal barrier, the high enrichment 
of MAIT cells in the liver and their rapid antimicrobial function render MAIT cells a 
plausible population that might contribute to both maintenance of liver and inflammation 
of liver in diseases (Bolte & Rehermann, 2018; Kurioka et al., 2016).  
 
MAIT cells express the tissue homing chemokine receptors CCR6, CXCR6, and the 
integrin αEβ7 in health and disease condition. However, in inflammation the intrahepatic 
MAIT cells expresses a higher level of CXCR3, a ligand for IFN inducible chemokine 
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CXCL9, CXCL10 and CXCL11 that are upregulated on inflamed liver sinusoids (Jeffery et 
al., 2016). Upon liver inflammation, MAIT cells can be activated by IL-18 that present at 
high levels in the inflamed liver, and by the MR1 dependent manner in which biliary 
epithelium cells can act as non-professional antigen presenting cells in addition to 
macrophages and liver B cells to release IFN-γ, TNF-α, IL-17 and granzyme B that drive 
killing of infected cells (Jeffery et al., 2016).  
 
In a study of MAIT cells in alcoholic liver disease, Riva et al. have reported depletion in 
blood MAIT cells accompaned with increasing the expression of the activation marker and 
impaired antimicrobial function that correlated with the disease severity. In addition, they 
refer this observation to the dysbiosis and loss of gut integrity that was well characterized 
in alcoholic liver disease patients (Riva et al., 2018). In chronic liver diseases, MAIT cells 
exhibit reduction in their frequency and impaired antimicrobial function which reduces of 
the liver immunity function and increase of bacterial infection susceptibility a major cause 
of mortality in cirrhosis (Bolte & Rehermann, 2018). Tang and colleagues found that 
MAIT cells function is regulated by IL-1, IL-23 and-7 that is secreted by hepatocytes 
during liver fibrosis. IL-17
+
 MAIT cells found to play a role in the pathogenesis of various 
chronic diseases, including alcoholic, metabolic, viral and autoimmune liver disease 
(Toubal & Lehuen, 2016). Bottcher et al. findings showed that MAIT cells induce hepatic 
stellate cells (HSC) proliferation and activation in which HSC produced a large amount of 
extracellular matrix protein that contributes to fibrosis. In addition, they found that this 
pro-fibrogenic role of MAIT cells is dependent on IL-17 and cell-cell contact between 
MAIT cells and HSCs (Bottcher et al., 2018). For their phenotype, function, and 
contribution in diseases, MAIT cells represent novel therapeutic, diagnostic and prognosis 
marker that is under investigation.  
 
1.4 Problem Statement 
NAFLD is a spectrum disease range from simple steatosis to steatosis with liver injury and 
inflammation that is termed as NASH. NASH has complications of cirrhosis and 
hepatocellular carcinoma (HCC). Around 13%of HCC is developed from NAFLD disorder 
(Paschos & Paletas, 2009). The prevalence of disease is rapidly increasing since it is 
associated with metabolic syndrome, especially obesity, diabetes mellitus and insulin 
resistance. In all stages of fibrosis, the disease is asymptomatic and lab test doesn’t 
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necessary reflect liver injury as ALT could only reflect acute liver disease and its levels are 
reduced along disease progressions (Oh et al., 2016). MAIT cells may play a role in the 
inflammation of the liver. However, the intervention of MAIT cells in the progression of 
NAFLD has not been explored. Thus, MAIT cells create an area for research to be used as 
diagnostic, prognostic and prospectively therapeutic tool. 
 
1.5  Study justification 
A liver biopsy is the gold standard method for the diagnosis of NAFLD. However, it has 
some limitations: It is an invasive method that holds a pain and a high risk to the patients . 
The cost of liver biopsy is high. The sample taken could lack accuracy and may not reflect 
the stage of the disease Inexperience pathologist (Pappachan et al., 2017). The research 
currently aims to focus on a MAIT cell as a cell population marker with good diagnostic 
and prognostic approach. MAIT cells are an attractive target that may interfere with the 
pathogenesis of NAFLD disease. MAIT cells are still not studied thoroughly and their 
function is not fully understood. 
 
1.6 Study Aims  
 To determine the frequency and phenotyping characteristics of MAIT cells in 
different stages of fibrosis in NAFLD patients as compared with healthy donors. 
 To evaluate the possibility of MAIT cells to predict the severity of liver fibrosis in 
NAFLD patients.  
 
1.7 Hypothesis 
 MAIT cells could be of a great significance in the diagnosis of NAFL disease and 
in the prediction of liver fibrosis stage in patients with NAFLD. 
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Chapter Two  
 
Materials and Methods 
 
2.1 Materials 
Materials and chemicals used in the experiment are: 
 
1. Sodium Citrate blood collection tubes or heparin blood collection tubes  
2. Plain blood collection tubes 
3. Phosphate buffer saline (PBS) (biological industries) 
4. Conical tubes  
5. 5mL polystyrene plastic tubes to apply in a flow cytometer 
6. Centrifuge 
7. Pipettes 
8. Ficoll-paque (isolation of mononuclear cells from human peripheral blood by 
density gradient centrifugation provided from Pharmacia) 
9. Easy step direct human T cell isolation kit (Miltenyi Biotec) 
10. EasyEights magnets (Catalog#18103) or the Big Easy magnet (Calalog#18001)  
11. Formaldehyde for fixation  
12. 0.1% saponine for permeabilization 
13.  Monoclonal antibodies (mAbs):  
I. Phycoerythrin(PE)-Cy7-A- conjugated anti TCR Vα7.2 (Miltenyi Biotec) 
II. Fluorescein isothiocyanate(FITC)-A- conjugated anti CD161(R&D systems 
USA) 
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III. Peridinin chlorophyll protein complex (PerCP)- conjugated anti CD69 
(R&D systems USA) 
IV. Pacific blue (PB)- conjugated anti tumor necrosis factor α (TNFα) (R&D 
systems USA) 
V. Allophycocyanin (APC) -A- conjugated anti interleukin 17 (IL-17) (R&D 
systems USA) 
VI. Allophycocyanin(APC) conjugated anti CD38 (R&D systems USA) 
VII. Peridinin chlorophyll protein complex (PerCP)- conjugated anti CD45 
(R&D systems USA) 
VIII. Pacific blue (PB)- conjugated anti CD3 (R&D systems USA) 
IX. Allophycocyanin (APC) -A- conjugated anti interleukin 17 (IL-17) (R&D 
systems USA) 
X. Allophycocyanin (APC) conjugated anti insulin receptor (R&D systems 
USA) 
XI.  An Isotype immunoglobulin G (IgG) for each antibody labeled with the 
corresponding fluorochrome used as control (from the same company of 
each antibody) 
14. BD LSR Fortessa (flow cytometer) 
15. Aluminium foil 
16. Ice  
17. Quantibody human cytokine array1 kit (RayBiotech, Inc. Cat#QAH-CYT-1) 
18. Distilled water 
19. Polypropylene Microcentrifuge tubes 
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2.2 Methods 
To summarize the methodology that was used, figure 2.1 is illustrated the design of the 
study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure (2.1) Flow chart for the methodology that was used.  
 
2.2.1 Study Population  
A stratified convenient sample of 25 histologically documented NAFLD cases with mean 
of 39.9±9.8 years and 5 healthy controls subjects with maen of 31±1.4 years were collected 
at Hadassah hospital between November2016 to July 2017. Additionally, three patients 
with cirrhosis and three healthy donors were recruited in January 2018. All the participiant 
were men to avoid the gender bias. 
Methodology 
Patients recruitment 
Clinical characterization  Blood sampling 
Cytokine measurment PBMCs extraction 
T cells extraction 
MAIT cells phenotyping  
(Flow cytometry) 
FA 
Statistical analysis 
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 Only NAFLD-patients were off therapy at the time of liver biopsy are included to avoid 
their phenotypic and functional effects on lymphocytes. Patients on steroid administration, 
recent use of warfarin, metformin, thiaglitazones and insulin for more than one month or 
any use in last 2 months, or daily alcohol intake >20 gm/day were excluded. Also cases 
with other competed etiology of liver disease, including viral hepatitis, autoimmune 
disease, hemochromatosis, Wilson's disease, alpha-1-antitrypsin disease, alcohol or any 
toxicity were excluded. 
 
2.2.2 Ethical considerations 
All subjects who agreed to precipitate were informed briefly about the subject and all 
signed approval consent (appendix 1) in conformity with the declaration of Helsinki. 
 
2.2.3 Clinical characterization 
Body mass index (BMI), serum cholesterol (LDL and HDL) and triglycerides (TG), serum 
levels of alanine aminotransferase (ALT), hemoglobin-A1c (HbA1c) levels, insulin 
resistance (calculated according to Homeostasis Model Assessment HOMA) and serum 
insulin levels were held from the patients' files in the hospital. All biopsies were assessed 
for the fibrosis severity using NAFLD activity score (NAS) and fibrosis score (Metavir) by 
pathologist.  
 
2.2.3.1. Homeostasis Model Assessment –insulin resistance HOMA-IR 
HOMA-IR is the most sensitive and specific method for measuring insulin resistance 
{Barseem, 2015 #11}. HOMA-IR was calculated using the formula: HOMA-IR = fasting 
glucose (nmol/L) × fasting insulin (µU/mL)/22.5. HOMA-IR values greater than or equal 
to 2.0 or 2.5 is the value used to distinguish between NAFLD patients and healthy controls 
(Tang et al., 2015).  
 
 2.2.3.2.NAFLD activity score (NAS) 
NAS calculated by the aggregate of scores of steatosis (0-3), lobular inflammation (0-3) 
and hepatocyte ballooning (0-2) with final score ranging from 0 to 8 (Goodman, 2007). 
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2.2.3.3.fibrosis score (Metavir) 
The Metavir score grades the level of fibrosis on a 5-point scale from 0 to 4 and the 
activity, which is the amount of inflammation, is scored on a 4-point scale from A0 to A3. 
Fibrosis score staged as: F0 = no fibrosis, F1 = perisinusoidal or periportal, F2 = 
perisinusoidal and periportal, F3 = bridging fibrosis, F4 = cirrhosis. The Activity score: A0 
= no activity, A1 = mild activity, A2 = moderate activity, A3 = severe activity (Goodman, 
2007). 
 
2.2.4 Sample Collection and Preparation 
Five heparin or sodium citrate tubes and one plain tube were collected from each 
participant at the time of liver biopsy. Plain tube was applied for measurement of certain 
cytokines in serum, whereas all heparin or citrate tubes were used for isolation of 
mononuclear cells by density gradient centrifugation. For more purity, peripheral blood 
mononuclear cells (PBMCs) were used. PBMCs were purified from heparinized or citrated 
blood by transferring all the five tubes to large tube and then a dilution with phosphate 
buffer solution (PBS) in one to one ratio was prepared. After that the diluted cell 
suspension was carefully added in 90° degree over a Ficoll-paque in one to one ratio. After 
centrifugation at 1600 rpm for 20 minutes without brake and accelerate, the mononuclear 
layer cell layer was carefully transferred to a new conical tube by pipette. The 
mononuclear cell layer was then centrifuged at 1600 rpm for 10 minutes at 4C° with brake 
and accelerates. After centrifugation the cell pellet was resuspended in 1ml of PBS for 
either immediate processing for the next step or for freezing at-20C°until used. 
 
2.2.5 Isolation of T cells using direct human T-cell isolation kit 
For more purity, direct human T-cell isolation kit was used in purifying T cell. The 
principal of the kit is to isolate T-cell from human blood samples by immunomagnetic 
negative selection. PBMCs that were purified by centrifugation over a Ficoll-paque 
gradient were applied to the kit according to the manufacturer's instructions (appendix 2). 
Following the kit instructions whole blood samples should be used, however, PBMCs 
samples were found to be more accurate to use.  
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2.2.6 Flow cytometric analysis 
The isolated cells that were obtained from direct human T cell isolation kit were 
centrifuged at 1600 rpm for 10 minutes. The pellet was then fixed by adding 20µl 
4%formaldehyde /100µl PBS for 1 minute on ice. Then 300µl of PBS were added and 
Centrifugation at 1600 rpm for 10 minutes in 4C° was done to stop the action of 
formaldehyde. The pellet then was resuspended in 300µl of PBS and stored in the 
refrigerator until the mixture of monoclonal antibodies was prepared. The monoclonal 
antibodies (mAbs) of anti TCR Vα7.2 (PE-Cy7), anti CD161 (FITC), anti IL-17 (APC) 
were used for all samples, whereas anti CD69 (PerCP), anti TNF-α (PB) and were used for 
all samples except of three F1 patients. Anti CD38 (APC) was used for some samples. The 
mixture of mAbs was prepared with ice by adding 2-5µl of each antibody diluted in PBS 
medium. For the intracellular staining of TNF-α and IL-17, 100µl of 0.1% saponine was 
added to the antibody mixture. Then the antibody mixture was added to the cells and 
incubated for 20-45 minutes on ice. Washing were performed to remove the unbound 
antibody was done three times by centrifugations at 1600rpm for 10 minutes at 4C° and 
adding 300 µl PBS for each time. Finally, the samples were analyzed by a flow cytometer 
(BD LSR Fortessa). Data were analyzed by FACS express3 software.  
 
Each sample was tested in triplicate. The mAbs are sensitive to light so they must be 
covered with aluminium foil. Unstained cells were used as negative control and to remove 
the possible effect of autofluorescence. Single staining cells were applied to determine the 
level of compensation. IgG isotypes control for each antibody labeled with the same 
fluorochrome of their corresponding were also used to remove the background staining. 
The variabilty in the antibodies that were used was due to the availabilty of these 
antibodies.  
 
2.2.7 Insulin receptor detection by flow cytometeric analysis  
Three F4 samples and three healthy samples were used for this experiment. Peripheral 
blood mononuclear cells (PBMCs) were pulled from the six samples by density gradient 
centrifugation as described in section 2.2.3. For flow cytometric analysis, the samples 
stained by anti CD45(pan leukocyte marker), anti CD3(pan T cell marker), anti CD161, 
anti TCR Vα7.2 and anti-insulin receptor as described in the previous section. 
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2.2.8 Cytokine measurement  
Cytokine levels were measured using quantibody human cytokine array 1 kit. Serum for 
five serum samples from each fibrosis stage except of F3 and five healthy samples were 
evaluated for their cytokine levels according to the manufacturer's instructions (appendix 
3). Multiplex Sandwich ELISA-based quantitative array is the precept of the kit. Data 
analysis of the multiple cytokines was performed using the Quantibody Q-Analyzer, an 
Excel-based program. Results are presented in pg/ml. The exception of F3 patients was due 
to that the wells were provided in the kit were not enough for all samples and F3 is 
histologically similar to F4.  
 
2.2.9 Statistical analysis 
Statistical analyses were performed using Microsoft Excel or Graph Pad Prism. Data were 
subjected to Kolmogorov-Smirnov normality test as well as to Shapiro-Wilk normality test 
and all data were normally distributed so parametric tests were used. All clinical, serum 
and histology parameters were compared between groups using the unpaired t-test. The 
flow cytometry results of patients and healthy donors were compared using un-paired t-
test. Pearson’s r coefficient for correlation test was used. Statistical significance was 
determined at p value ≤ 0.05.  
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Chapter Three 
 
Result 
 
3.1 HOMA-IR scores are associated with increased liver fibrosis 
Twenty-five NAFLD patients fulfilled the inclusion/exclusion criteria, all are men with 
mean age of 39.3±9.8 years and BMI mean of 29.19±9. The patients were stratified 
according to their fibrosis score as shown in Table (3.1).  
 
We found that LDL levels in NAFLD patients were within the borderline range (130-159 
mg\dl). Whereas, the HDL levels and the TG levels in the patients were within the normal 
range (40-50 mg\dl in men, 150-500mg\dl, respectively). The cholesterol profile findings 
indicate that this profile can not be used in the prediction of NAFLD. We also observed 
that there was no significant differences in age, ALT, Triglyceride, High density 
lipoprotein and Low density lipoprotein were noted between fibrosis score categories.  
 
BMI was not significantly correlated with the increased fibrosis score in our population 
with p value equal 0.052. As expected HbA1c was within the normal ranges since the 
selected patient population presented mild metabolic complications and were free of 
medications. Increased fibrosis score significantly correlated with histologically detected 
necro-inflammatory activity and the serum level of C-reactive protein. The patients were 
share high CRP levels as the normal range of CRP is less than 1. This high level of CRP 
was correlated with the inflammation process of NAFLD. 
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HOMA scores levels were increased in F2,F3 and F4 patients with scores higher than the 
normal range ( more than 2 is consider IR). In addition, serum insulin were also higher 
than the normal range (less than 25mIU\ml) in advanced fibrosis stages. Moreover, the 
increased in the HOMA scores and serum insulin was significantly correlated with fibrosis 
score progressions and was prominent in patients with advanced fibrosis (p=0.001 and 
p=0.05, respectively). 
 
Table3.1: Characteristics of NAFLD patients according to Fibrosis score  
Characteristics 
Healthy 
n =5 
Fibrosis (Metavir Score) (n=25) 
P-
value 
F1(1.2±0.8) 
n =6 
F2(1.9±0.5) 
n =6 
F3(3.1±0.4) 
n =6 
F4(3.5±0.4) 
n =7 
Age [years] 31±14 36.6±9.9 38.9±8.7 40.7±11 41.1±9.4 NS 
BMI 27.1±3.8 28.35±7.9 29.15±7.9 29.4±10.1 29.85±9.9 0.052 
LDL cholesterol 
[mg/dl] 
121±17.5 131.7±26.6 124.7±21.4 134.7±29.1 143.7±29.1 NS 
HDL cholesterol 
[mg/dl]  
44±6.7 40.8±8.4 37.6±9.6 37.3±6.5 38.5±3.5 NS 
Triglycerides 
[mg/dl] 
144±20.6 147.8±39.5 146.7±31.6 150.2±27.7 151.2±29.3 NS 
ALT [IU/L] 77.1±13.4 79.5±47.7 81.3±35.5 78.9±35.0 89±35.7 NS 
Inflammatory 
activity [A] 
NA 1.4±0.7 1.6±0.6 2.0±0.0 2.2±0.5 0.02 
CRP (mg/dl)  2.7±1.1 3.1±1.7 3.3±1.5 4.1±1.7 4.5±2.3 0.005 
HbA1c [%] 3.5±0.45 3.3±0.8 4.9±0.4 3.9±0.3 5.6±0.3 0.0006 
Insulin levels 
(mIU/ml) 
NA 20.1±3.8 24.7±4.1 25.7±2.1 27.8±5.1 0.05 
HOMA-IR  NA 1.8±0.2 3.0±1.1 3.3±1.0 5.2±0.2 0.001 
 
NAFLD: Non Alcoholic Fatty Liver Disease, HOMA: homeostasis model assessment, LDL: low-density 
lipoproteins, HDL: high-density lipoproteins, TG: triglycerides, ALT: alanine aminotransferase, HbA1c: 
Hemoglobin A1C. CRP: c reactive protein. HOMA-IR (homeostasis model assessment –insulin resistance) 
 
3.2 Depletion in the frequency of MAIT cells in F4 NAFLD patients 
Human MAIT cells are defined as CD161
++
 Vα7.2+. We determined the frequency of 
MAIT cells in our samples by flow cytometry using anti-Vα7.2 and anti-CD161 after 
isolation of CD3+ cells by human T cell isolation kit (Figure 2.1A, 2.1B). 
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Figure (3.1): .A) Representative dot plot of flow cytometry analysis of the CD3
+
 cells. B) Shows the gate 
drawn on our potential population, identified asVα7.2+CD161+. 
 
A significant depletion in the frequency of circulating MAIT cells was observed in F3-F4 
patients with a mean frequency of 1.66%, 1.4% of T cells, respectively. Whereas the mean 
frequency of MAIT cells in F2 was 3.97% of T cells and F1 patients were 10.62% of T 
cells. Healthy MAIT cell frequency range was 11.2%-14.2% of T cells (Figure 3.1.C, 
p<0.0001). We also found that the reduction in the frequency of MAIT cells in NAFLD 
patients can predict severity of disease, as we found a significant difference among stages. 
The p values of F1-F2, F2-F3 and F3-F4 were found to be far less than 0.05 (not shown in 
the figure). 
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Figure (3.1.C) Percentages of MAIT cells among T cells in patients with NAFLD stages. Each symbol 
represents the value of one individual. The middle line indicates the mean. * p=0.025, ***p<0.001 assessed 
by t test. 
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3.3 Activation of MAIT cells is associated with increased liver fibrosis 
Activation of Mucosal associated invariant T (MAIT) cells was determined by studying the 
early activation marker CD69 and CD38. After the determination of our potential 
population as double positive staining cells of CD161 and TCRVα7.2 in flow cytometry, 
the percentages of cells express CD69 and CD38 was detected by flow cytometry using 
anti-CD69 (Figure 3.2.A) and anti-CD38. 
 
 
Figure (3.2.A) Flow cytometry dot plot represents the percentages of CD69 expressing cells. 
 
An increase in the expression of CD69 was observed to be proportional to the increasing of 
fibrosis score, as well in CD38. The mean of the percentages of CD38
+
 among MAIT cells 
was higher in advanced stages of fibrosis in which F3 and F4 patients CD38
+
 cells was 
20.1% and 32.7%, respectively, as compared with 8.5% in healthy subjects (Figure 3.2.B). 
Whereas the mean of the percentages of CD69
+
 among MAIT cells was 42.3,70.8%, 73.7% 
and 78.4% in F1, F2, F3 and F4 patients, respectively, which is higher than the mean 
percentages of CD69
+ 
cells among MAIT cells in healthy that 9.6% (Figure 3.2.C).  
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Figure (3.2.B) Percentages of CD69
+
 cells among MAIT cells in patients with NAFLD stages. Each symbol 
represents the value of one individual. The middle line indicates the mean. ****p<0.0001 assessed by t test. 
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Figure (3.2.C) Percentages of CD38
+
 cells among MAIT cells in patients with NAFLD stages. Each symbol 
represents the value of one individual. The middle line indicates the mean. * p=0.026, ***p<0.001 assessed 
by t test. 
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We also found that the increased in the expression of CD38 was significantly difference 
among stages. The p values of F1-F2, F2-F3 and F3-F4 were 0.043, 0.002, 0.0007, 
respectively. This significantly augmented expression was not found with CD69 among 
F2-F3 and F3-F4. However, there was a significant increased in the expression of CD69 
between F1-F2 patients with p value of 0.00001. 
 
The activation of MAIT cells as was determined by the expression of CD69 was inversely 
correlated with MAIT cell frequency (r= -0.95, p=0.011) as shown in figure (3.2.D).  
 
 
Figure (3.2.D) The correlation between MAIT cells frequency and CD69
 
expression.  
 
3.4 Increased the frequency of IL-17+ MAIT cells is correlated with increased liver 
fibrosis 
As MAIT cells produce IL-17 upon activation, a pro-fibrogenic cytokine that were found 
to be involved in the hepatic fibrosis development in autoimmune liver fibrosis and non-
autoimmune liver fibrosis (Bottcher et al., 2018; Toubal & Lehuen, 2016). To assess the 
frequency of IL-17
+
 MAIT cells, the cells were stained with anti-IL-17 and analyzed by 
flow cytometry (Figure 3.3.A) 
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Figure (3.3.A) A flow cytometry dot plot represents the percentages of IL-17
+
 MAIT cells  
 
There was a significantly higher IL-17
+
 MAIT cells in liver fibrosis patients when 
compared to healthy subjects as seen in figure (3.3.B). Moreover, this elevation was 
significantly different among stages. The p values were less than 0.05 among F1-F2 and 
F3-F4, but not between F2-F3 with p value of 0.03.  
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Figure (3.3.B) Percentages of IL-17
+
 cells among MAIT cells in patients with NAFLD stages. Each symbol 
represents the value of one individual. The middle line indicates the mean. ***p<0.001 assessed by t test. 
 
IL-17 positive cells were found to be inversely correlated with the frequency of MAIT 
cells, this illustrated in figure (3.3.C). 
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Figure (3.3.C) The correlation between MAIT cells frequency and IL-17+ MAIT cells. 
 
 
3.5 Increased TNF-α expression in F4 NAFLD patients  
We further detected other immunological marker, the tumor necrosis factor α (TNF-α), a 
pro-inflammatory cytokine contributes to the hepatic inflammation, apoptosis of liver cells 
and induces the insulin resistance (Seo et al., 2013). The frequency of TNF-α+ cell among 
MAIT cells was determined by flow cytometer using anti-TNF-α as seen in figure (3.4.A)  
 
Figure (3.4.A) A flow cytometry dot plot represents the percentages of TNF-α+ MAIT cells 
 
Figure (3.4.B) shows a significant increase in the expression of TNF-α in F1, F2, F3, and 
F4 when compared with healthy subjects. However, this elevation was found to be elevated 
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mostly in F1 patients followed by a significant depletion in F2 (p<0.0005) then return to be 
significantly augmented in F3 (p=0.01) after that a non significant elevation found in F4.  
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Figure (3.4.B) Percentages of TNF-α+ cell among MAIT cells in patients with NAFLD stages. Each symbol 
represents the value of one individual. The middle line indicates the mean. ****p<0.0001 assessed by t test. 
 
3.6 Alterations in the cytokine levels in the serum of NAFLD patients 
To get an indication about the inflammatory cytokines that could mediate the stimulation 
of MAIT cells, the patients’ sera tested to multiple cytokines using quantibody human 
cytokine array 1. From the twenty cytokines tested, nine of them underwent a significant 
alteration which are IL-1a, IL-1b, IL-2, IL-6, IL-12p70, IL-13, GM-CSF, TNF-α and 
MMP-9 (Figure 3.5, p<0.05).  
 
The inflammatory cytokine IL-1, TNFα, GM-CSF and IL-12 were significantly increased 
during the progression of the disease that may reflect a chronic activation of MAIT cells. 
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Figure (3.5) Means of the cytokine level detected in the sera of 5 patients from each fibrosis stage F1, F2 and F4 and 5 healthy donors. N=5 in each group. P<0.05 between F1 
and F4 groups. 
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3.7 Decreased expression of insulin receptor in F4 NAFLD patients 
For this experiment, we utilized six PBMCs samples, three from healthy individuals and 
three from F4 NAFLD patients to detect their insulin receptor expression. CD45 a pan 
leukocyte marker and CD3 pan T cell marker were used to determine T lymphocyte 
population. Then double positive cells for CD161 and Vα7.2 were determined as MAIT 
cell population. After that, insulin receptor expression in MAIT cells was assessed. As 
shown in figure (3.6), the insulin receptor was significantly reduced in F4 patients with 
mean insulin receptor positive cells of 2.4%, as compared with 6.03% a mean insulin 
receptor positive cells expressed on MAIT cells of healthy donors (p=0.021). 
 
 
Figure (3.6) Percentages of insulin receptor
+ 
cell among MAIT cells in patients with F4 stage. P=0.021 
assessed by t test. 
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Chapter Four 
 
Discussion 
 
4.1 Discussion 
In the present study, we examined the frequency and the function of MAIT cells in 25 
NAFLD patients with different stage of fibrosis compared to five healthy donors. Seven of 
the NAFLD patients developed cirrhosis accompanied by hyperinsulinemia and insulin 
resistance. Mean age at biopsy was 39.3±9.8 and BMI mean was 29.19±9. Insulin 
resistance (calculated by HOMA scores) and insulin serum levels in our patient population 
increased during fibrosis progression which correlated with the consideration that NAFLD 
is the hepatic manifestation of the metabolic syndrome (Bolte & Rehermann, 2018). We 
also found that the body mass index (BMI) was increased with increased liver fibrosis 
score as reported with other studies (Zelber-Sagi et al., 2017). However, this elevation was 
not significantly which might be attributed to the small sample size. Similary, we found 
that the necro-inflammatory activity and the serum level of C-reactive protein was 
significantly increased with fibrosis progression and was associated with increased the 
serum level of inflammatory cytokines (figure 3.5). We found an insignificant differences 
in age, ALT, Triglyceride, High density lipoprotein and Low density lipoprotein between 
fibrosis score categories. In contrast with a study by Hossain et al. on 432 patients with 
histologically proven NAFLD in which they revealed that ALT and AST can be used as 
predictor for fibrosis as they increased with advanced fibrosis stage (Hossain et al., 2009). 
However, a recent longitudinal study revealed that liver steatosis is the best predictor for 
fibrosis progression rather than the clinical and biochemical parameters (Lallukka et al., 
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2017). In our study, insulin resistance calculated by HOMA score can be used as a 
metabolic predictor for liver fibrosis. 
 
Non-alcoholic fatty liver disease (NAFLD) is a spectrum disease that includes a simple 
steatosis to NASH; a progressive form of steatosis accompanied with inflammation and 
injury and with or without fibrosis. 20% of NASH patients might further progress to 
cirrhosis which increase the risk of hepatocellular carcinoma and liver failure. The 
prevalence of disease is increasing with an estimation of 1 billion people worldwide have 
NAFLD. The disease is asymptomatic and the reliable diagnostic procedure is the liver 
biopsy. The prevalence is thought to be higher than estimated. Thus, there is a need to non-
invasive method for diagnosis. Moreover, there is no effective treatment for NAFLD which 
increases the demand on focusing more on the disease management (Zhang et al., 2018). 
The liver is enriched with immune cells. One of the largest T cells population in the liver is 
MAIT cells, a novel innate like T cells that have the ability to recognize riboflavin 
metabolite derived from microbes and also can be stimulated by cytokines that suggest the 
important role of MAIT cells in the immunity and homeostasis of the liver (Kurioka et al., 
2016). 
  
We investigated the frequency of MAIT cells present in our study population which are 
defined as cells with double positive for CD161 and Vα7.2. We demonstrated depletion in 
the circulating MAIT cells in patients with NAFLD. A study by Jeffery at al. found a 
similar depletion in the circulating MAIT cells in patients with chronic liver diseases 
including alcoholic steatohepatitis, primary sclerosing cholangitis and primary biliary 
cirrhosis (Jeffery et al., 2016). Despite the reduction in the circulating MAIT cells, we 
observed an increase in the activation of MAIT cells as detected by the expression of the 
activation marker CD69 and CD38.  
 
The depletion and the activation of MAIT cells was reported in other chronic liver diseases 
with different etiology (Bolte et al., 2017; Bottcher et al., 2018; Riva et al., 2018). We also 
demonstrated that the depletion and the activation of MAIT cell levels in the peripheral 
blood of NAFLD patients in correlation with the severity of fibrosis.  
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In addition, we found an elevation in the serum levels of inflammatory cytokine IL-1α, IL-
1β, IL-6, TNF-α, GM-CSF and IL-12 (figure3.5). This elevation was associated with 
fibrosis progression as in advanced fibrosis stages, the level of these cytokines was higher. 
This finding was correlated with increased the activation level of MAIT cells, which may 
elicit the independent activation manner mediated by cytokine.  
 
Gut dysbiosis is found to be correlated with NAFLD (Pappachan et al., 2017). That might 
give an additional possible way of MAIT cell activation by bacteria translocation from the 
gut to the liver. 
 
The dramatic reduction in MAIT cell levels could be as a result of their recruitment to the 
site of infection which is expected. MAIT cells known to own a variety of chemokine 
receptor enable them to migrate to different tissues or might be due to activation induced 
cell death mechanism that MAIT cells underwent as a result to the chronic exposure to the 
inflammatory cytokine. These phenomena was suggested by others in many inflammatory 
diseases including ankylosing spondylitis, systemic lupus erythematosus and alcoholic 
liver diseases (Chiba et al., 2017; Gracey et al., 2016; Riva et al., 2018).  
 
Furthermore, we investigated the immune phenotype of MAIT cells through the 
intracellular staining of IL-17 and TNF-α. IL-17 has the profibrogenic effect on hepatic 
stellate cells that suggest the possible role of MAIT cells in the fibrosis development 
(Bottcher et al., 2018). We found that IL-17
+
 MAIT cells were elevated through the 
fibrosis progression.  
 
In addition, we found an elevation in TNF-α+ MAIT cells in NAFLD patient as compared 
with healthy donors. However, the upregulation of TNF-α was mostly in F1 that might 
indicate an acute response. TNF-α is an inflammatory cytokine which contributes to the 
hepatic inflammation, apoptosis of liver cells and induces the insulin resistance. The 
activation of proinflammatory pathways after exposure to TNF-α induces a state of insulin 
resistance in which TNF-α impair insulin signalling at the level of the insulin receptor 
substrate (IRS) proteins (Seo et al., 2013).  
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Down regulation of insulin renders effector T cells to be less proliferated and cytotoxic and 
to produce less proinflammatory cytokine which means loss of function condition (Fischer 
et al., 2017). So for future, we will focus on detecting the functional alteration of MAIT 
cells in NAFLD. 
 
 4.2 Conclusions  
 
The current study demonstrates that the clinical and biochemical markers failed to predict 
the liver fibrosis in patients with NAFLD. However, insulin resitance calculated with 
HOMA score might be used as predictor marker for NAFLD. 
 
Our study also revealed that the circulating MAIT cells are reduced and activated when 
compared to healthy donors as well, when compared among stages. Thus, reflecting the 
severity of fibrosis. In addition, MAIT cells was found to express more IL-17 and TNF-α 
than the healthy individual. We also noticed that insulin receptor was down regulated in 
cirrhotic patients than healthy donors. Thus, suggesting a possible less proliferative and 
less functional MAIT cells might be present in advanced fibrosis NAFLD patients. 
 
 These finding suggested the possible role of MAIT cells in the pathogenesis of non-
alcoholic liver disease (NAFLD). That nominates the MAIT cells to be used as a predictor 
for liver fibrosis in NAFLD diagnosis and prognosis approaches.  
 
4.3 Weaknesses or limitations in the current study plan 
 
The first limitation was the sample size. It was difficult to collect samples fulfill the 
inclusion and exclusion criteria in this short period of time. The other limitation was not to 
perform the functional assay for MAIT cells to assess the functional diversity in NAFLD 
disease.  
 
4.4 Recommendations 
MAIT cell is considered a new T cell population that seems to have a promising role in 
many diseases. For future, functional assay for circulating MAIT cells in NAFLD patients 
will decipher more about the role of MAIT cell in the progression of NAFLD.  
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تتوقع شدة تميف الكبد في المرضى الذين يعانون من   )TIAM(خلايا التائية المحيطة بالأغشية
 )DLFAN( مرض الكبد الدهني غير الكحولي
 
  البكري عيسى عبد الفتاح اعداد: دانيه
 د.جوني عامر شراف:إ
 ممخص:
 بالمنتجات تنشيطيا نيمك التي التائية الخلايا من فرعية مجموعة من تتكون TIAM(( خلايا مقدمة :
 دور عن القميل سوى يعرف لا. semyznarg و 71-LI و α-FNT لإنتاج والسيتوكينات البكتيرية
 . غير الكحولي الدىني الكبد مرض في التميف تطور في TIAM خلايا
 تميف شدةىذه الظواىر مع  ارتباط والعلامات الظاىرية ليا ومدى TIAM خلاياعدد  تقييم الأهداف :
 .DLFAN مرضى في بدالك
اصحاء في ىذه  2و  العمر،غير الكحولي  الدىني الكبدمريضا ب 22تم مشاركة  الطرق والمواد :
 و، الصيام في الانسولين ومستويات ،) TLA ناقمة الامين الألانين( الجسم، كتمة مؤشرالدراسة. 
و البروتين الدىني ،ةو الدىون الثلاثي، )RI-AMOHمقاومة الانسولين ( و، مستوى تخزين السكر
 درجات معتم ربطيا  )PRC( Cالبروتين المتفاعل و و البروتين الدىني منخفض الكثافة،مرتفع الكثافة
 مسببات من غيرىا أو الأيض متلازمة إلى ونفتقر ي الذين البالغين في DLFAN حالات في التميف
و . DLFANوالمرضى  صحاءالأ المتبرعين من ى عينات الدمعم الحصول تم ، المختبر في. الكبد
 قياس باستخدام ثم .تائية نقية خلايا عمى حصمنا ،tik noitalosi llec T namuh tcerid باستخدام
 RCT و 161DC التي تحتوي عمى TIAM خلايا حددنا ،)yrtemotyc wolF(الخموي التدفق
 09
 
 
مناعية لفحص العلامات ال 71LIو 83DC و 96DC و αFNT مثل علامات حددنا كما. 2.7αV
 في السيتوكين مستويات اكتشفنا ،1 yarra enikotyc namuh ydobitnauq باستخدامو . لمخلايا
عمى  الأنسولين مستقبلات وجود حددنا ،yrtemotyc wolF الخموي التدفق قياس باستخدام. الدم
  .من الدرجة الرابعة مرضى ثلاثة في TIAM سطح خلايا
 ، ذكورل العينات كانت جميع ،لمعينات الاستبعاد/  التضمين معايير تستوفا حالة 22 :النتائج 
 سبعة. 9 ± 91.92 ومتوسط مؤشر الجسم كان ،سنة 8.9 ± 3.93 الخزعة عند العمر متوسط
 أىموجد انو  )RI-AMOH(. ة الرابعةدرجمن ال وا يعانون من التميفكان حيث الكبد تشمع من يعانون
تم ملاحظة و  TIAM خمية 11.1± ٪ 12.21 الأصحاء رعينالمتب لدى كان. تميفال لخطورة مؤشر
 و 13.1± ٪ 22.01 إلى DLFAN من يعانون الذين لممرضى TIAMخلايا  في ممحوظ نقص
 و 3F و 2F و1Fالتميف  درجات مع 12.0± ٪ 2.1 و 10.0± ٪ 22.1 و 11.0± ٪ 3.3
 التنشيط علامات في عارتفا المرضى من TIAM خلايا أظيرت ، ذلك عمى علاوة. التوالي ،عمى4F
 تظير أيضا ارتفاع في TIAM خلايا كانت. الاصحاء المانحين مع مقارنة،83DC و 96DC مثل
 ىذه كانت. للالتياب مؤيد سيتوكين وىو ، αFNT عن فضلا ، للألياف مؤيد سيتوكين وىو ،71-LI
-LI ذلك في بما ةلالتيابيا اتالسيتوكين في ارتفاع كما لاحظنا. التميف شدة مع خطًيا مترابطة النتائج
 4F مرضى في الأنسولين مستقبلات في انخفاضايضا  لوحظ. TIAM خلايا بتنشيط عرفذي يال 21
 .الأصحاء المتبرعين مع مقارنة
. التميف مرحمة مع عكسياارتباطا  ترتبط DLFAN مرضى في TIAM خلايا انخفاض :الاستنتاج 
 ىدفا ً تمثلقد و  DLFAN مرضى في التميف تطور في ىماتس قد TIAM خلايا أن إلى بياناتنا تشير
 .جديًدا تشخيصيا ً
 
